The announcement of a cost reduction program is typically viewed positively by investors as it suggests a focus on improving profitability and financial discipline. For Novavax, targeting significant reductions in R&D and SG&A expenses could lead to improved margins and potentially a stronger bottom line. This strategic move is likely to be seen as a proactive step in managing expenses, which could result in a positive short-term impact on the stock price.